References

ophthalmology

Офтальмология

Ophthalmology in Russia

1816-50952500-0845

Ophthalmology

10.18008/1816-5095-2023-4-634-640

ophthalmology-2231

Research Article

ОБЗОРЫ

REVIEWS

Латанопрост в лечении первичной открытоугольной глаукомы. Обзор

Xalatan in the Treatment of Primary Open-Angle Glaucoma. Review

https://orcid.org/0000-0003-0057-3338

Лоскутов

И. А.

Loskutov

I. A.

Лоскутов Игорь Анатольевич доктор медицинских наук, руководитель офтальмологического отделения

ул. Щепкина, 61/2, Москва, 129110

Loskutov Igor A. MD, the head of Ophthalmologic department

Schepkina str., 61/2, Moscow, 129110

https://orcid.org/0000-0002-7242-8781

Андрюхина

О. М.

Andruhina

O. M.

Андрюхина Ольга Михайловна кандидат медицинских наук, старший научный сотрудник офтальмологического отделения

ул. Щепкина, 61/2, Москва, 129110

Andruhina Olga M. PhD, senior research officer

129110, Schepkina str. 61/2, Moscow

ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского»РоссияMoscow Regional Research and Clinical Institute (MONIKI)Russian Federation

2023

27122023

204634640

2023

Лоскутов И.А., Андрюхина О.М.

Loskutov I.A., Andruhina O.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.ophthalmojournal.com/opht/article/view/2231

За последние 25 лет Ксалатан (латанапрост) стал одним из наиболее эффективных препаратов первой линии в лечении глаукомы из-за выраженного гипотензивного действия, безопасности и удобства однократного инстиллирования. В обзорной статье представлены исторические аспекты создания и механизмы действия аналогов простагландина, нейропротекторные свойства латанапроста, а также данные метаанализов и клинических исследований об эффективности препарата в лечении глаукомы.

Over the past 25 years, Xalatan (Latanaprost) has become one of the most effective first-line drugs in the treatment of glaucoma, due to its pronounced hypotensive effect, safety and convenience of a single instillation. The review article presents the historical aspects of the creation and mechanisms of action of prostaglandin analogs, the neuroprotective properties of latanoprost, as well as data from meta-analyses and clinical studies on the effectiveness of the drug in the treatment of glaucoma.

глаукомалатанопростКсалатананалоги простагландиновнейропротекциялечение

glaucomalatanoprostXalatanprostaglandin analoguesneuroprotectiontreatment

обзор подготовлен при поддержке компании «Виатрис»

The review is supported by Viatris.

References1

Senjam SS. Glaucoma blindness-A rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Family Med Prim Care. 2020 May 31;9(5):2200–2206. doi: 10.4103/jfmpc.jfmpc_111_20.

Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013.

Егоров Е.А., Егоров А.Е., Елисеева Т.О., Егорова Т.Е. Нежелательные явления гипотензивной терапии глаукомы. РМЖ. Клиническая офтальмология. 2011;12(3):111–113.

Egorov EA, Egorov AE, Eliseeva TO, Egorova TE. Undesirable effects of hypotensive treatment of glaucoma. Literary review. Russian Journal of Clinical Ophthalmology. 2011;12(3):111 –113 (In Russ).

Киселева О.А., Якубова Л.В., Бессмертный А.М. Бета-блокаторы в лечении глаукомы: история и перспективы. Эффективная фармакотерапия. 2018;(22):14–17.

Kiseleva OA, Yakubova LV, Bessmertny AM. Beta-blockers in the treatment of glaucoma: history and prospects. Effective pharmacotherapy. Ophthalmology. 2018;2:4–17 (In Russ).

Астахов ЮС, Нечипоренко ПА. Аналоги простагландинов: прошлое, настоящее и будущее. Офтальмологические ведомости 2017;10(1):40–52.

Astakhov YS, Nechiporenko PA. Prostaglandin analogues: past, present, and future. Ophthalmology journal. 2017;10(1):40–52 (In Russ).

Егорова Т.Е. Простагландины в лечении глаукомы. РМЖ. Клиническая офтальмология. 2004;5(3):127–132.

Egorova TE. Prostaglandins in glaucoma treatment Literary review. Literary review. Russian Journal of Clinical Ophthalmology. 2004;5(3):127–132 (In Russ).

Shaw JE, Ramwell PW. Prostaglandins: a general review. Res Prostaglandins. 1971 Jun;1(1):1–8.

Jansook P, Loftsson T. Aqueous Prostaglandin Eye Drop Formulations. Pharmaceutics. 2022 Oct 9;14(10):2142. doi: 10.3390/pharmaceutics14102142.

Егоров А.Е., Глазко Н.Г., Мовсисян А.Б. Гипотензивная и нейропротективная терапия глаукомы: реалии и перспективы. РМЖ. Клиническая офтальмология. 2019;19(3):128–135. doi: 10.32364/2311-7729-2019-19-3-128-135.

Egorov AE, Glazko NG, Movsisyan AB. IOP-lowering and neuroprotective treatment for glaucoma: reality and prospects. Russian Medical Journal. Clinical Ophthalmology. 2019;19(3):128–135 (In Russ). doi: 10.32364/2311-7729-2019-19-3-128-135.

Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years’ experience. Br J Ophthalmol. 2009 Dec;93(12):1572–1575. doi: 10.1136/bjo.2008.151522.

Russo A, Riva I, Pizzolante T, Noto F, Quaranta L. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol. 2008 Dec;2(4):897–905.

Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996 Apr;7(2):11–17. doi: 10.1097/00055735199604000-00003.

Stjernschantz J, Selén G, Sjöquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513–518.

Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998 Aug;67(2):179–191. doi: 10.1006/exer.1998.0508.

Lindsey JD, Gaton DD, Sagara T, Polansky JR, Kaufman PL, Weinreb RN. Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment. Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1781–1786.

Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci. 2013 Jul 16;54(7):4782–4790. doi: 10.1167/iovs.13-12363.

Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996 Nov;9(5):363-78. doi: 10.2165/00002512-199609050-00007.

Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977 Dec;16(12):1125–1134.

Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005 % once daily versus 0.0015 % twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5 %. Graefes Arch Clin Exp Ophthalmol. 1997 Jan;235(1):20–26. doi: 10.1007/BF01007833.

Hogg HDJ, Connor A. 10-year trends in English primary care glaucoma prescribing. Eye (Lond). 2020 Jan;34(1):192–196. doi: 10.1038/s41433-019-0656-z.

Tanito M. Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan. J Pers Med. 2022 Jun 11;12(6):956. doi: 10.3390/jpm12060956.

Perera N, Pinnuck BC, Jamieson MPH, Ling D, Williams M, Chen O. Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017. J Glaucoma. 2020 Mar;29(3):175–183. doi: 10.1097/IJG.0000000000001414.

Yu L, Ding K, Luo L, Yu Z. Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLoS One. 2020 Jan 13;15(1):e0227595. doi: 10.1371/journal.pone.0227595. Erratum in: PLoS One. 2020 Mar 13;15(3):e0230694.

Schmier JK, Covert DW, Robin AL. First-year treatment patterns among new initiators of topical prostaglandin analogs. Curr Med Res Opin. 2009 Apr;25(4):851–858. doi: 10.1185/03007990902791132.

WHO web link: https://www.who.int/publications/i/item/WHO-MHP-HPSEML-2021.02

Лоскутов И.А., Корнеева А.В. Комплексная оценка применения латанопроста в клинической практике: медико-статистическое наблюдение. Национальный журнал Глаукома. 2019;18(3):20–28. doi: 10.25700/NJG.2019.03.02

Loskoutov IA, Korneeva AV. Complex assessment of Latanoprost use in clinical practice: the results of a questionnaire survey. National Journal glaucoma. 2019;18(3):20–28 (In Russ.) doi: 10.25700/NJG.2019.03.02

https://pubmed.ncbi.nlm.nih.gov/?term=latanoprost

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701–713; discussion 829–830. doi: 10.1001/archopht.120.6.701.

Mohamed A, Han JE, Galiyev Y, Henein C, Mathew RG. Infographic: Collaborative Initial Glaucoma Treatment Study (CIGTS). Eye (Lond). 2021 Oct;35(10):2665–2666. doi: 10.1038/s41433-021-01434-z.

Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268–1279. doi: 10.1001/archopht.120.10.1268.

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429–440. doi: 10.1016/s0002-9394(00)00538-9.

The effectiveness of intraocular pressure reduction in the treatment of normaltension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998 Oct;126(4):498–505. doi: 10.1016/s0002-9394(98)00272-4.

Rouland JF, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, Baudouin C; T2345 Study Group. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013 Feb;97(2):196–200. doi: 10.1136/bjophthalmol-2012-302121.

Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC; Xplore Observation Group. Two-year follow-up of latanoprost 0.005 % monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004 Dec;20(6):470–478. doi: 10.1089/jop.2004.20.470.

Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J; Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004 Sep;111(9):1627–1635. doi: 10.1016/j.ophtha.2004.02.017.

Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566–2573.

Varma R, Hwang LJ, Grunden JW, Bean GW. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol. 2008 Feb;145(2):336–342. doi: 10.1016/j.ajo.2007.10.002.

Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008 Jul;115(7):1117–1122.e1. doi: 10.1016/j.ophtha.2007.10.004.

Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, Sellem E, Amrane M. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010 Feb 24;10:4. doi: 10.1186/1471-2415-10-4.

Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004 Jul;122(7):957–965. doi: 10.1001/archopht.122.7.957.

Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016 Jan;123(1):129–140. doi: 10.1016/j.ophtha.2015.09.005.

Kulkarni SV, Damji KF, Buys YM. Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. Patient Prefer Adherence. 2008 Feb 2;2:303–314. doi: 10.2147/ppa.s4163.

Heo JH, Rascati KL, Wilson JP, Lawson KA, Richards KM, Nair R. Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension. J Manag Care Spec Pharm. 2019 Sep;25(9):1001–1010. doi: 10.18553/jmcp.2019.25.9.1001.

Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials. J Ocul Pharmacol Ther. 2009 Feb;25(1):55–64. doi: 10.1089/jop.2008.0080.

European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021 Jun;105(Suppl 1):1–169. doi: 10.1136/bjophthalmol2021-egsguidelines.

Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, Rajadhyaksha V. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007 Mar-Apr;55(2):127–131. doi: 10.4103/0301-4738.30707.

Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res. 2012 Feb;37(2):101–108. doi: 10.3109/02713683.2011.631722.

Leitritz MA, Lipp HP, Voykov B, Ziemssen F. Originalpräparat versus Generika-Latanoprost : Wie gleich ist unterschiedlich? [Original preparations versus generics--latanoprost: how similar is different?]. Ophthalmologe. 2015 Feb;112(2):127–139. German. doi: 10.1007/s00347-014-3097-x.

Leitritz MA, Lipp HP, Voykov B, Ziemssen F. Originalpräparat versus GenerikaLatanoprost : Wie gleich ist unterschiedlich? [Original preparations versus generics--latanoprost: how similar is different?]. Ophthalmologe. 2015 Feb;112(2):127–139. German. doi: 10.1007/s00347-014-3097-x.

Kolko M, Koch Jensen P. The physical properties of generic latanoprost ophthalmic solutions are not identical. Acta Ophthalmol. 2017 Jun;95(4):370–373. doi: 10.1111/aos.13355.

Painter SL, Mead AL. Patient experience of the transition from Xalatan to generic latanoprost. Eye (Lond). 2014 Jul;28(7):911. doi: 10.1038/eye.2014.71.

Gossman CA, Christie J, Webster MK, Linn DM, Linn CL. Neuroprotective Strategies in Glaucoma. Curr Pharm Des. 2016;22(14):2178–2192. doi: 10.2174/1381612822666160128144747.

Zheng J, Feng X, Hou L, Cui Y, Zhu L, Ma J, Xia Z, Zhou W, Chen H. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011 May;31(4):597–604. doi: 10.1007/s10571-011-9653-x.

Shinozaki Y, Koizumi S. Potential roles of astrocytes and Müller cells in the pathogenesis of glaucoma. J Pharmacol Sci. 2021 Mar;145(3):262–267. doi: 10.1016/j.jphs.2020.12.009. Epub 2020 Dec 31.

Yamamoto K, Sato K, Yukita M, Yasuda M, Omodaka K, Ryu M, Fujita K, Nishiguchi KM, Machida S, Nakazawa T. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. J Neurochem. 2017 Feb;140(3):495–508. doi: 10.1111/jnc.13902. Epub 2016 Dec 27.

Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res. 2009 Mar;88(3):535–541. doi: 10.1016/j.exer.2008.11.012.

Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel GM, Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res. 2006 Nov;83(5):1108–1117. doi: 10.1016/j.exer.2006.05.018.

Kudo H, Nakazawa T, Shimura M, Takahashi H, Fuse N, Kashiwagi K, Tamai M. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):1003–1009. doi: 10.1007/s00417-005-0215-0.

Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, Li T, Mansberger SL; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021 Jan;128(1):P71–P150. doi: 10.1016/j.ophtha.2020.10.022.

Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295–1304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19. Erratum in: Lancet. 2015 Jul 11;386(9989):136.

Казанова С.Ю. Побочные эффекты аналогов простагландинов, используемых в офтальмологической практике. Российский офтальмологический журнал. 2021;14(2):85–89. doi: 10.21516/2072-0076-2021-14-2-85-89.

Kazanova SYu. Adverse effects of prostaglandin analogues used in ophthalmological practice. Russian Ophthalmological Journal. 2021;14(2):85–89 (In Russ.). doi: 10.21516/2072-0076-2021-14-2-85-89.

Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003 May;135(5):688–703. doi: 10.1016/s0002-9394(03)00098-9.

Lin L, Zhao YJ, Chew PT, Sng CC, Wong HT, Yip LW, Wu TS, Bautista D, Teng M, Khoo AL, Lim BP. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585–1593. doi: 10.1177/1060028014548569.

Guedes RA, Guedes VM, Freitas SM, Chaoubah A. Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clin Ophthalmol. 2012;6:1749–1753. doi: 10.2147/OPTH.S37347.

Oh JY, Park KH. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Korean J Ophthalmol. 2005 Dec;19(4):297–301. doi: 10.3341/kjo.2005.19.4.297.

Konstas AG, Koliakos GG, Karabatsas CH, Liakos P, Schlötzer-Schrehardt U, Georgiadis N, Ritch R. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Exp Eye Res. 2006 Feb;82(2):319–322. doi: 10.1016/j.exer.2005.07.004.

Курышева Н.И. Новые возможности и перспективы использования латанопроста (Ксалатан, Pfizer, США) в лечении псевдоэксфолиативной глаукомы. Офтальмологические ведомости. 2013;6(1):61–65.

Kurysheva NI. The new advantages and perspectives of Latanoprost (Xalatan, Pfizer, USA) treatment in pseudoexfoliation glaucoma. 2013;6(1):61–65 (In Russ.).

Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, Katsanos A, Longo A, Uva MG, Oddone F, Torri V, Weinreb RN. The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results. J Glaucoma. 2018 Oct;27(10):856–863. doi: 10.1097/IJG.0000000000001038. PMID: 30095601.

Жукова О.В., Золотарёв А.В. Эффективность латанопроста при различных формах глаукомы и внутриглазной гипертензии у детей. РМЖ. Клиническая офтальмология. 2014;14(4):185–188.

Zhukova OV, Zolotarev AV. Effect of latanoprost in various types of glaucoma and ocular hypertemsion in children. Russian Journal of Clinical Ophthalmology.2014;14(4):185–188 (In Russ.).

Younus M, Schachar RA, Zhang M, Sultan MB, Tressler CS, Huang K, Xu W, Klein M, Platt RW, Mukherjee N, Haenel E, Freedman SF. A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. Am J Ophthalmol. 2018 Dec;196:101–111. doi: 10.1016/j.ajo.2018.08.039.

Miki T, Naito T, Fujiwara M, Araki R, Kiyoi R, Shiode Y, Fujiwara A, Morizane Y, Shiraga F. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017 Jul 20;12(7):e0181550. doi: 10.1371/journal.pone.0181550.

Agange N, Mosaed S. Prostaglandin-induced cystoid macular edema following routine cataract extraction. J Ophthalmol. 2010;2010:690707. doi: 10.1155/2010/690707. Epub 2010 Nov 7.

Астахов С.Ю., Астахов Ю.С., Гобеджишвили М.В. Влияние лечения аналогами простагландинов на толщину сетчатки после факоэмульсификации с имплантацией интраокулярной линзы у больных первичной открытоугольной глаукомой. Офтальмологические ведомости. 2014;7(3):73–76. doi: 10.17816/OV2014373-76.

Astakhov SYu, Astakhov YuS, Gobedzhishvili MV. The influence of prostaglandin analogs on the retinal thickness after phacoemulsification with intraocular lens implantation in primary open-angle glaucoma patients .Ophthalmology Reports. 2014;7(3):73–76 (In Russ.). doi: 10.17816/OV2014373-76.

Moghimi S, Zandian M, Latifi G, Amini H, Eslami Y, Zarei R, Fakhraie G, Nouri-Mahdavi K. Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery. J Ophthalmic Vis Res. 2012 Oct;7(4):289–294.

Moghimi S, Zandian M, Latifi G, Amini H, Eslami Y, Zarei R, Fakhraie G, NouriMahdavi K. Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery. J Ophthalmic Vis Res. 2012 Oct;7(4):289–294.

Иошин И.Э., Толчинская А.И. Аналоги простагландинов при факоэмульсификации катаракты на фоне первичной глаукомы. РМЖ. Клиническая офтальмология. 2016;16(4):185–191. doi: 10.21689/2311-7729-2016-16-4-185-191.

Ioshin IE, Tolchinskaya AI. Prostaglandin analogues in cataract surgery by phacoemulsification in patients with primary glaucoma Russian Medical Journal. Clinical Ophthalmology. 2016;16(4):185–191 (In Russ.). doi: 10.21689/2311-7729-2016-16-4-185-191.

The authors declare that there are no conflicts of interest present.